

TEMPLE UNIVERSITY
INSTITUTIONAL BIOSAFETY COMMITTEE
IBC Meeting Minutes- Online Meeting
June 16, 2026 12:01 pm

Members

X	Black, Dr. Mark- Community Member
X	Bradley, Carlos- Community Member
X	Culmer-Butler, Dr. Dorian- Animal Containment Expert
X	Escalante, Dr. Ananias- Scientist
X	Forste, Dr. Dawn- Animal Containment Expert
X	Gallo, Dr. Gianluca- Scientist
X	Lupinski, Gregory- EHRS Executive Director
X	Mobo, Dr. Ben Hur Jr.- Occupational Health Administrator
X	Moore, Claudia- IACUC Asst. Director
X	Murray, Krista- IBC Assistant Director
	Pultro, Mary- IBC Sr. Coordinator
	Sariyer, Dr. Ilker- IBC Vice-Chair, Scientist
X	Sawaya, Dr. Bassel- Scientist
X	Sulistijo, Dr. Endah- University Biosafety Officer
X	Tsygankov, Dr. Alexander- IBC Chair, Scientist
X	Whelan, Dr. Kelly- Scientist
	Wimmer, Dr. Mathieu- Scientist

X= Present

Quorum was met for this meeting.
All decisions were unanimous.

Guests

Baglia, Frank- Senior Health & Safety Specialist
Hao, Lanping- Associate Health & Safety Specialist
Khan, Sabina- Senior Health & Safety Specialist
Kidder, Abigail- IACUC Analyst
Ladman, Dr. Brian- future Community Member
Slupianek, Dr. Artur- Senior Director of Research Regulatory Affairs
Wright, Simone- IBC Analyst

I. Announcements

Ms. Murray announced that, upon review of the IBC registration this year, they determined that Dr. Black does not meet their definition of a non-affiliated community member now. Because of this, we have to identify a new non-affiliated community member. This is the last meeting that Dr. Black will be attending. The committee thanked Dr. Black for his service and contributions to the IBC.

Ms. Murray introduced Dr. Brian Ladman, who will be joining the IBC as of July 1, 2026 as the new non-affiliated community member. The IBC members introduced themselves to Dr. Ladman and welcomed him to the committee.

II. Other Business

Dr. Sulistijo informed the committee that the Select Agent program performed a remote inspection of the Temple program on June 3 and 4, 2026. The report is expected in the next few weeks.

Ms. Murray thanked the IBC members who provided input for the IBC program Self-Assessment. She stated that anyone who still wanted to provide comments could. The IBC office is reviewing the input provided and the points will be discussed in the upcoming meetings.

III. Minutes Reviewed

Minutes from the May 19, 2026 meeting were reviewed. The motion to approve the minutes was made and approved unanimously, with one abstention.

IV. Protocols Reviewed

PI: Kishore, Raj	Reg: 11371	Activity: 6 Year Rewrite	NIH: III-D-4; III-E-3	BSL: 2
Title: Cellular and Molecular Approaches for Cardiac and Vascular Repair and Impacts on Other Organ Systems				
Overview: The delivery of therapeutics through cell-based and cell-free approaches that can reverse the damage that occurs in patients who have suffered heart failure or critical limb ischemia utilizing in vitro and in vivo projects.				
Discussion: The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices. Need to clarify room numbers, clarify adenovirus vs. adeno-associated virus use, and fix some administrative items.				
Final Action: modifications required				

PI: Jensen, Liselotte	Reg.: 11369	Activity: 6 Year Rewrite	NIH: III-D-4, 7; III-E-3	BSL: 2
Title: Skin Inflammation				
Overview: To use a series of well-established models to determine how different genes affect the outcome of inflammation and/or infection.				
Discussion: The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices. Clarify disposal procedures; some administrative modifications required.				
Final Action: modifications required				

PI: Sebastian, Robin	Reg.: 11299	Activity: Amendment	NIH: III-D-1	BSL: 2
Title: Elucidating Mechanisms of Genome Stability During DNA Replication				
Overview: Addition of lentiviral transduction for the generation of stable cell lines.				
Discussion: The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices. Clarify if lab will produce LVV in-house.				
Final Action: modifications required				

PI: Kaminski, Rafal	Reg.: 11250	Activity: Amendment	NIH: III-D-1, 2, 3	BSL: 2+
Title: Developing and Validating CRISPR-Based Anti-Viral Approaches				

Overview: Addition of new cells, Zika virus, and CRISPR gene targets.
Discussion: The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices. Clarify safety level and work procedures for Zika virus. Work with Occupational Health on medical monitoring requirements.
Final Action: modifications required

PI: Kutlu, Munir	Reg.: 11240	Activity: Amendment	NIH: III-D-4	BSL: 1
Title: Predicting Maladaptive Aversive Learning via Computational Modeling of Insular Single-Cell Ensemble Activity Patterns				
Overview: Addition of AAV plasmids for stereotaxic injections.				
Discussion: The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices.				
Final Action: approved				

PI: Smith, George	Reg.: 10890	Activity: Amendment	NIH: III-D-2, 3, 4; III-E-1	BSL: 2
Title: Role of Mitochondrial Fragmentation in Axonal Regeneration After SCI, Mechanisms for Recovery of Skilled Forelimb Function in Neonatal Rats, Enhancing Propriospinal Relays to Improve Functional Recovery After SCI, STAT3 Expression Prevents Neurodegeneration in Hemi-Parkinson's Model				
Overview: Addition of 2 plasmids in vivo for optogenetic inhibition and activation.				
Discussion: The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices. Clarify whether plasmids are for adenovirus or adeno-associated virus. Will they be used for viral vector expression? Will the lab propagate them or purchase them ready to use?				
Final Action: modifications required				

PI: Khalili, Kamel	Reg.: 11034	Activity: Amendment	NIH: III-D-2, 3, 4; III-E-1, 3	BSL: 2+
Title: Cas9/gRNA Editing for Viral Therapeutics in Vitro and in Vivo				
Overview: Addition of plasmids for CRISPR based editing experiments.				
Discussion: The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices. Clarify use of SIV derived viral vector.				
Final Action: modifications required				

PI: Zhang, Wei	Reg.: 11244	Activity: Amendment	NIH: III-D-1, 3, 4; III-E-3	BSL: 2
Title: Understanding the DDX21-Dependent Regulatory Role of lncRNA INKILN in Ribosome Biogenesis and Vasculopathy				
Overview: Use of lipid and polymer-based nanoparticles encapsulating either mRNA or pomalidomide for in vivo studies.				
Discussion: The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices. Pomalidomide is a hazardous drug- need to add it as such.				
Final Action: modifications required				

PI: Arzumanyan, Alla	Reg.: 11050	Activity: Amendment	NIH: NA	BSL: 2
Title: Rapid Response Development of Molecular Lego-Like SYMBAs for the Attenuated (BSL2) Strain of <i>Yersinia pestis</i>				
Overview: Transfer of <i>Bartonella henselae</i> procedures to this protocol from previously approved protocol.				

Discussion: The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices.
Final Action: approved

PI: Tam, Vincent	Reg.: 11129	Activity: Amendment	NIH: III-D-1, 2, 3, 4, 7; III-E-3	BSL: 2
Title: Resolution of Inflammation During Microbial Infection				
Overview: Addition of plasmids for mammalian cell culture work.				
Discussion: The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices.				
Final Action: approved				

PI: Rajadhyaksha, Anjali	Reg.: 11172	Activity: Amendment	NIH: III-D-4; III-E-3	BSL: 1
Title: The Neurobiological and Neurocircuitry Effects of Drugs of Abuse; Mouse Breeding Protocol				
Overview: Addition of tamoxifen, new mouse lines, and adeno-associated viruses (AAVs).				
Discussion: The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices. Provide the reason for the additional AAVs and mouse lines. Confirm hazardous drug training and signatures on tamoxifen SOP.				
Final Action: modifications required				

PI: Zhou, Zhengjie	Reg.: 11294	Activity: Amendment	NIH: III-D-4	BSL: 2
Title: Precision Nanomedicine Targeting Pulmonary Inflammatory Mechanisms				
Overview: Addition of: 1) siRNA-loaded nanoparticles treating H1N1-induced lung injury; 2) mRNA-loaded lipid nanoparticle (LNP) delivery to neutrophils treating H1N1-induced lung injury; 3) use of InVivoMAb anti-mouse PD-L1 IP in mice after LPS- and H1N1-induced lung injury and flow cytometry; 4) use of Tamoxifen in mice.				
Discussion: The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices. Confirm training for use of tamoxifen and biosafety level for various procedures.				
Final Action: modifications required				

PI: Arzumanyan, Alla	Reg.: 11191	Activity: Amendment	NIH: NA	BSL: 3
Title: Rapid Response Development of Molecular SYMBAs for Yellow Fever Virus and Western Equine Encephalitis Virus				
Overview: Transfer of Chikungunya virus and Zika virus procedures to this protocol from a previously approved protocol.				
Discussion: The IBC reviewed the procedures, containment level, facilities to be used, lab member training, containment procedures and work practices.				
Final Action: approved				

V. Adjournment

The motion to adjourn the meeting was approved unanimously; the meeting adjourned at 1:41 pm.

Respectfully submitted,

Krista Murray

Krista Murray
Institutional Biosafety Committee Assistant Director